WS Investor
23 Mar 2026, 19:43
Abbott announced it has completed the acquisition of Exact Sciences, strengthening its position in cancer screening and diagnostics.
The deal expands Abbott’s portfolio with leading products such as Cologuard and Oncotype DX, while adding a pipeline focused on early cancer detection and personalized treatment.
The acquisition positions Abbott to compete in a fast-growing $60 billion market, supporting its strategy to advance preventative and precision healthcare solutions.
PRNewswire
The deal expands Abbott’s portfolio with leading products such as Cologuard and Oncotype DX, while adding a pipeline focused on early cancer detection and personalized treatment.
The acquisition positions Abbott to compete in a fast-growing $60 billion market, supporting its strategy to advance preventative and precision healthcare solutions.
PRNewswire
